Sign in
Taking peoplePhase 1

Testing the safety of IBI3031 in people with thyroid eye disease

Tests IBI3031 against placebo for safety in adults with thyroid eye disease.

Key facts

Who runs it
Innovent Biologics (Suzhou) Co. Ltd.
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
A Study of IBI3031 in Participants With Thyroid Eye Disease
Status
Recruiting
Phase
Phase 1
People taking part
66 people, planned
Started
30 Jun 2026
Expected to end
28 Dec 2027
Type of study
Interventional, 16 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • IBI3031
  • placebo
Record updated
14 July 2026

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 28 criteriaShow less

Who can take part

  • Written informed consent
  • Aged between 18 and 75 years at screening
  • Weight between 45 kg and 100 kg
  • Moderate-to-severe active TED:; CAS ≥ 3 in the study eye at screening and baseline; Usually associated with at least two of the following: lid retraction ≥ 2 mm, moderate or severe soft tissue involvement, exophthalmos ≥ 3 mm above normal, and/or inconstant or constant diplopia; ≤ 12 months since the onset of active TED symptoms according to subjects' chief complaint or medical record at screening
  • Exophthalmos ≥ 18 mm in the study eye at baseline. (Only applicable to Stage 2)
  • Participants must be clinically and biochemically euthyroid, or have mild hypothyroidism or mild-to-moderate hyperthyroidism at screening
  • Positive for Thyrotrophin Receptor Antibody (TRAb) at screening
  • No prior treatment with antithyroid medications and/or thyroid hormone replacement therapy, or having taken antithyroid medications and/or thyroid hormone replacement therapy on a stable dose for at least 6 weeks prior to the first dose, or having not been treated with antithyroid medications and/or thyroid hormone replacement therapy due to intolerable side effects for at least 6 weeks prior to the first dose
  • Infertile female participants or fertile female participants with negative blood pregnancy test results during the screening period and agree to take contraceptive measures from screening to 120 days after the last dose; male participants should agree to use contraceptive measures from screening to 120 days after the last dose

Who cannot take part

  • Participants previously diagnosed with dysthyroid optic neuropathy (DON), or with DON as determined by the investigator at screening
  • Scheduled radioactive iodine therapy or thyroidectomy at any time before screening or during the study
  • Scheduled orbital radiotherapy at any time before screening or during the study, or surgical treatment for TED, including orbital decompression, strabismus surgery, and eyelid surgery
  • Cumulative dose of glucocorticoids used to treat TED ≥ 1 g of methylprednisolone equivalents within 90 days prior to screening
  • Oral or intravenous glucocorticoids within 30 days prior to screening
  • Peribulbar/periorbital injection of glucocorticoids within 90 days prior to screening
  • Oral or intravenous administration of any other non-steroidal immunosuppressants within 90 days prior to screening
  • Use of glucocorticoid eye drops/ointments or use of non-steroidal immunosuppressant eye drops within 14 days prior to screening
  • Received antibody therapy targeting IGF-1R, TSHR, CD20(cluster of differentiation antigen 20), IL-6, or IL-6 receptor (IL-6R) at any time before screening
  • Received any other TED therapeutic drugs under development (including but not limited to biologics targeting IGF-1R, FcRn(neonatal Fc recepto), IL-6, or IL-6R) at any time before screening
  • Use of any other monoclonal antibody within 90 days prior to screening
  • Have received live vaccines within 180 days prior to screening, or plan to receive live vaccines during the study
  • Presence of other non-TED ophthalmic diseases that may affect the interpretation of study results or the safety of participants as determined by the investigator (e.g., proptosis not primarily caused by TED)
  • At screening, clinical or laboratory evidence of significant hypothyroidism (presence of clinical symptoms of hypothyroidism, or FT3 or FT4 (Free Thyroxine)<0.5×lower limit of normal [LLN], or TSH>1.5×upper limit of normal [ULN]); or severe hyperthyroidism during the screening period (FT3 and FT4(Free Thyroxine)>2×ULN, or presence of thyroid storm)
  • Other medical history and abnormal test results during the screening period that are judged by the investigator to be clinically significant, may cause the participant to fail to comply with the study protocol or complete the trial, or endanger safety, including but not limited to:; History of hepatic insufficiency (Child-Pugh Class B or C) or liver cirrhosis; aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2 × ULN at screening; Glomerular filtration rate (GFR) < 60 ml/min/1.73 m2; Poorly controlled diabetes mellitus or hypertension; Confirmed or clinically suspected inflammatory bowel disease, gastrointestinal bleeding, or peptic ulcer disease; History of of chronic or recurrent infections; opportunistic infection within 180 days prior to screening; Positive for human immunodeficiency virus antibody (HIV Ab), hepatitis C virus antibody (HCV Ab), non-specific syphilis antibody (e.g., RPR(Rapid Plasma Reagin), TRUST), hepatitis B virus surface antigen (HBsAg) or e-antigen (HBeAg), or interferon-gamma release assay (IGRA); History of tinnitus or other hearing impairment in either ear during the screening period; or abnormal pure tone audiometry results (defined as an average bone conduction hearing threshold of ≥ 25 dB(decibe) at 0.5, 1, 2, and 4 kHz(kilohertz), or a bone conduction hearing threshold of ≥ 40 dB at any frequency)
  • Participants to be excluded (Participants meeting any of the following criteria will be regarded as ineligible):
  • The CAS of the study eye at baseline is reduced by ≥ 2 points compared with that at screening, or the proptosis of the study eye at baseline is reduced by ≥ 2 mm compared with that at screening
  • Patients with corneal ulcers that are not relieved after treatment at the investigator's discretion
  • Female participants in pregnancy or lactation

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a multicenter, randomized, double-masked, placebo-controlled, single/multiple-dose-escalation trial conducted in Chinese participants with Thyroid Eye Disease (TED), aiming to evaluate the safety and tolerability of IBI3031 administered via subcutaneous or intravenous injection.

The 16 groups in the trial

  • SAD Dose 4 - Placebo Control GroupPlacebo, for comparison

    Subjects receive matching placebo to the treatment group.

    Treatment: placebo

  • MAD Dose 2- IBI3031A101 Treatment GroupTreatment being tested

    Multiple ascending dose (MAD) phase. Subjects receive repeated doses of IBI3031A101 to evaluate safety, tolerability and steady-state pharmacokinetics.

    Treatment: IBI3031

  • SAD Dose 4 - IBI3031A101 Treatment GroupTreatment being tested

    Subjects receive single-dose IBI3031A101 at different dose levels to evaluate safety, tolerability and pharmacokinetics.

    Treatment: IBI3031

  • MAD Dose 1 - Placebo Control GroupPlacebo, for comparison

    Multiple ascending dose (MAD) phase. Subjects receive matching placebo to the treatment group.

    Treatment: placebo

  • MAD Dose 1- IBI3031A101 Treatment GroupTreatment being tested

    Multiple ascending dose (MAD) phase. Subjects receive repeated doses of IBI3031A101 to evaluate safety, tolerability and steady-state pharmacokinetics.

    Treatment: IBI3031

  • MAD Dose 3 - Placebo Control GroupPlacebo, for comparison

    Multiple ascending dose (MAD) phase. Subjects receive matching placebo to the treatment group.

    Treatment: placebo

  • SAD Dose 5 - IBI3031A101 Treatment GroupTreatment being tested

    Subjects receive single-dose IBI3031A101 at different dose levels to evaluate safety, tolerability and pharmacokinetics.

    Treatment: IBI3031

  • MAD Dose 2 - Placebo Control GroupPlacebo, for comparison

    Multiple ascending dose (MAD) phase. Subjects receive matching placebo to the treatment group.

    Treatment: placebo

  • SAD - Dose 1 - Placebo Control GroupPlacebo, for comparison

    Subjects receive matching placebo to the treatment group.

    Treatment: placebo

  • SAD Dose 3 - IBI3031A101 Treatment GroupTreatment being tested

    Subjects receive single-dose IBI3031A101 at different dose levels to evaluate safety, tolerability and pharmacokinetics.(at the same dose level as Arm 2 but via \[different route/method)

    Treatment: IBI3031

  • SAD Dose 2 - IBI3031A101 Treatment GroupTreatment being tested

    Subjects receive single-dose IBI3031A101 at different dose levels to evaluate safety, tolerability and pharmacokinetics.

    Treatment: IBI3031

  • SAD Dose 5 - Placebo Control GroupPlacebo, for comparison

    Subjects receive matching placebo to the treatment group.

    Treatment: placebo

  • SAD Dose 3 - Placebo Control GroupPlacebo, for comparison

    Subjects receive matching placebo to the treatment group.

    Treatment: placebo

  • MAD Dose 3- IBI3031A101 Treatment GroupTreatment being tested

    Multiple ascending dose (MAD) phase. Subjects receive repeated doses of IBI3031A101 to evaluate safety, tolerability and steady-state pharmacokinetics.

    Treatment: IBI3031

  • SAD - Dose 2 - Placebo Control GroupPlacebo, for comparison

    Subjects receive matching placebo to the treatment group.

    Treatment: placebo

  • SAD Dose 1 - IBI3031A101 Treatment GroupTreatment being tested

    Subjects receive single-dose IBI3031A101 at different dose levels to evaluate safety, tolerability and pharmacokinetics.

    Treatment: IBI3031

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of IBI3031 in Participants With Thyroid Eye Disease
Plain-language title
Testing the safety of IBI3031 in people with thyroid eye diseaseGenerated from the registry record. The registry title is the official one.
Criteria questions
Built from NCT07622368, who can take part
Record updated
14 July 2026